Patenting cDNA 1993: efforts and happenings

The National Institute of Health (NIH) and Dr.J.C. Venter applied for patents for the sequences of cDNA fragments from a brain library. The scientific community objected strenuously on emotional grounds. The NIH argues that these sequences might never be patentable even when completed. The issue bec...

Full description

Saved in:
Bibliographic Details
Published inGene Vol. 135; no. 1; pp. 295 - 298
Main Author Zinder, Norton D.
Format Journal Article Conference Proceeding
LanguageEnglish
Published Lausanne Elsevier B.V 15.12.1993
Amsterdam Elsevier
New York, NY
Subjects
Animals
Biological and medical sciences
DNA, Complementary
Europe
European Patents
Fundamental and applied biological sciences. Psychology
Genes. Genome
Genetics - legislation & jurisprudence
Human Genome Project
Humans
Mice
Molecular and cellular biology
Molecular genetics
National Institutes of Health (U.S.)
NIH
onco-mouse
Oncogenes
Patents as Topic - legislation & jurisprudence
United States
US PTO
United States
Europe
European Patents
STS
US PTO
onco-mouse
nt
cDNA
PTO
NIH
Human Genome Project
bp
Patents
Complementary DNA
Nucleotide sequence
Legislation
Online AccessGet full text

Cover

More Information
Summary:The National Institute of Health (NIH) and Dr.J.C. Venter applied for patents for the sequences of cDNA fragments from a brain library. The scientific community objected strenuously on emotional grounds. The NIH argues that these sequences might never be patentable even when completed. The issue became an international one with the British applying for patents to protect their position while the French, Italians and Japanese vowed not to patent cDNA. The United States Patent Trademark Office (US PTO) strongly rejected the NIH's application. The NIH is appealing the decision.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0378-1119
1879-0038
DOI:10.1016/0378-1119(93)90080-M